3,351 results match your criteria Transitional Cell Carcinoma Renal

Sarcomatoid variant of urothelial carcinoma in the renal pelvis with brain metastasis: a case report.

Pan Afr Med J 2022 22;41:233. Epub 2022 Mar 22.

Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.

Sarcomatoid urothelial carcinoma (UC) of the renal pelvis is rare. It is a high-grade malignant tumor that contains both epithelial and mesenchymal elements. Brain metastases from renal pelvis UC are infrequent and represented in few cases. Read More

View Article and Full-Text PDF

A web-based prognostic nomogram for the cancer specific survival of elderly patients with T1-T3N0M0 renal pelvic transitional cell carcinoma based on the surveillance, epidemiology, and end results database.

BMC Urol 2022 May 24;22(1):78. Epub 2022 May 24.

Department of Urology; Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical Research Center for Child Health and Disorders (Chongqing); China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Chongqing Key Laboratory of Pediatrics, Children's Hospital of Chongqing Medical University, 2 ZhongShan Rd, Chongqing, 400013, People's Republic of China.

Background: At present, there are few studies on renal pelvic transitional cell carcinoma (RPTCC) in elderly patients in the literature. The study aims to establish a new nomogram of cancer-specific survival (CSS) in elderly patients with T1-T3N0M0 RPTCC and validate its reliability.

Methods: This study downloaded the data of 1375 elderly patients with T1-T3N0M0 RPTCC in the Surveillance, Epidemiology, and Final Results (SEER) database from 2004 to 2018. Read More

View Article and Full-Text PDF

Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers.

Am Soc Clin Oncol Educ Book 2022 Apr;42:1-16

Division of Oncology 1, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD.

The role of adjuvant therapy in renal cell carcinoma and urothelial carcinoma is rapidly evolving. To date, the U.S. Read More

View Article and Full-Text PDF

Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.

J Med Case Rep 2022 May 18;16(1):193. Epub 2022 May 18.

Department of Urology, Nagano Municipal Hospital, 1333-1, Tomitake, Nagano, Nagano, Japan.

Background: Collecting duct carcinoma and sarcomatoid renal cell carcinoma are tumors with poor prognosis. Immune checkpoint inhibitors have been established as the standard treatment for advanced renal cell carcinoma. Some cases of remission of collecting duct carcinoma and sarcomatoid renal cell carcinoma have been reported using immune checkpoint inhibitor interventions. Read More

View Article and Full-Text PDF

A Novel Machine Learning 13-Gene Signature: Improving Risk Analysis and Survival Prediction for Clear Cell Renal Cell Carcinoma Patients.

Cancers (Basel) 2022 Apr 24;14(9). Epub 2022 Apr 24.

Bioinformatics Multidisciplinary Environment (BioME), Metropole Digital Institute (IMD), Federal University of Rio Grande do Norte (UFRN), Natal 59078-400, Brazil.

Patients with clear cell renal cell carcinoma (ccRCC) have poor survival outcomes, especially if it has metastasized. It is of paramount importance to identify biomarkers in genomic data that could help predict the aggressiveness of ccRCC and its resistance to drugs. Thus, we conducted a study with the aims of evaluating gene signatures and proposing a novel one with higher predictive power and generalization in comparison to the former signatures. Read More

View Article and Full-Text PDF

Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution.

Cancer Treat Res 2022 ;183:201-223

Division of Urology, Taichung Veterans General Hospital, 1650, Taiwan Boulevard Sect. 4, Taichung, Taiwan, 40705.

Immunotherapy, the 5th pillar of cancer care after surgery, radiotherapy, cytotoxic chemotherapy, and precision therapy (molecular targeted therapy), is revolutionizing the standard of care in certain patients with genitourinary malignancies. As modest clinical benefits of IL-2 for metastatic renal cell carcinoma and Bacillus Calmette-Guerin therapy for early-stage bladder cancers in the past years, immune checkpoint inhibitors therapies demonstrate meaningful survival benefit and durable clinical response in renal cell carcinoma, urothelial carcinoma, and some prostate cancer. Despite best efforts, the benefits are limited to a minority of unselected patients due to the complexities of biomarker development. Read More

View Article and Full-Text PDF

A surgical case of high-grade urothelial carcinoma of the renal pelvis complicated with giant hydronephrosis, giving rise to diagnostic difficulties on a cytological examination.

Diagn Pathol 2022 May 11;17(1):47. Epub 2022 May 11.

Kanazawa Medical University Hospital, 1-1, Ishikawa, 920-0293, Uchinada, Japan.

Background: We report a surgical case of urothelial carcinoma of the renal pelvis, resulting in diagnostic difficulties on cytological examination.

Case Presentation: A man in his late 70s underwent nephrectomy for giant hydronephrosis and renal cysts after nephrostomy and renal cyst puncture and drainage. On all cytological examinations performed before surgery, including nephrostomy urine, renal cyst fluid, catheterized bladder urine, and bladder washings, we were unable to make any conclusive diagnosis of malignancy. Read More

View Article and Full-Text PDF

Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses.

J Infus Nurs 2022 May-Jun 01;45(3):142-153

Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio (Ms Wood); University of Chicago Medicine, Genitourinary Oncology, Chicago, Illinois (Ms Conway); St Bartholomew's Hospital, London, United Kingdom (Ms Lapuente, Mr Salvador, Ms Fernandez Gomez); St George's Hospital, London, United Kingdom (Ms Fernandez Gomez); EMD Serono, Rockland, Massachusetts (Ms Carroll Bullock); Pfizer Inc, New York, New York (Dr Devgan); City of Hope Medical Center, Genitourinary Medical Oncology, Duarte, California (Ms Burns).

Immune checkpoint inhibitors, such as programmed cell death ligand 1 inhibitors pembrolizumab, nivolumab, atezolizumab, and avelumab, are used to treat patients with advanced urothelial carcinoma (UC). Based on data from the phase 3 JAVELIN Bladder 100 trial, avelumab first-line (1L) maintenance is now considered the standard-of-care treatment for patients with locally advanced or metastatic UC who responded or experienced disease stabilization after 1L platinum-containing chemotherapy, and it is the only category 1 preferred checkpoint inhibitor maintenance option in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for patients with cisplatin-eligible and cisplatin-ineligible locally advanced or metastatic UC. This article reviews key considerations related to avelumab 1L maintenance therapy that infusion nurses should be familiar with, including dosing, administration, and immune-related adverse event recognition and management, to ensure safe and appropriate use of this important and impactful therapy. Read More

View Article and Full-Text PDF

Papillary Renal Cell Carcinoma With "Drop Metastasis" (Tumor Seeding) Involving the Distal Ureter.

Mayo Clin Proc 2022 05;97(5):1026-1028

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

View Article and Full-Text PDF

MiR-26a-5p as a useful therapeutic target for upper tract urothelial carcinoma by regulating WNT5A/β-catenin signaling.

Sci Rep 2022 04 28;12(1):6955. Epub 2022 Apr 28.

Department of Urology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 83301, Taiwan, ROC.

The role of miRNAs in cancer and their possible function as therapeutic agents are interesting and needed further investigation. The miR-26a-5p had been demonstrated as a tumor suppressor in various cancers. However, the importance of miR-26a-5p regulation in upper tract urothelial carcinoma (UTUC) remains unclear. Read More

View Article and Full-Text PDF

Use of immunotherapy in clinical management of genitourinary cancers - a review.

Cancer Treat Res Commun 2022 17;31:100564. Epub 2022 Apr 17.

University of California Irvine, Division of Hematology/Oncology, USA.

Checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 have revolutionized oncologic care delivery, including clinical management of genitourinary malignancies. Despite significant associated improvement in patient outcomes, molecular heterogeneity of tumors, variable tumor engagement with the immune response, and unique patient factors likely account for different clinical responses to immunotherapy agents. A search for predictive biomarkers of treatment response to checkpoint inhibitors is underway and several candidates, although imperfect, have been identified. Read More

View Article and Full-Text PDF

Phase II Clinical and Translational Study of Everolimus ± Paclitaxel as First-Line Therapy in Cisplatin-Ineligible Advanced Urothelial Carcinoma.

Oncologist 2022 Jun;27(6):432-e452

The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Background: Treatment options have been historically limited for cisplatin-ineligible patients with advanced urothelial carcinoma (UC). Given the need for alternatives to platinum-based chemotherapy, including non-chemotherapy regimens for patients with both impaired renal function and borderline functional status, in 2010 (prior to the immune checkpoint blockade era in metastatic UC), we initiated a phase II trial to test the activity of everolimus or everolimus plus paclitaxel in the cisplatin-ineligible setting.

Methods: This was an open-label phase II trial conducted within the US-based Hoosier Cancer Research Network (ClinicalTrials. Read More

View Article and Full-Text PDF

Zirconium-labelled girentuximab (Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma.

BMJ Open 2022 04 15;12(4):e060478. Epub 2022 Apr 15.

Urology, Fiona Stanley Hospital, Murdoch, Western Australia, Australia.

Introduction: Bladder cancer is a lethal disease with a rising incidence on a background of limited conventional imaging modalities for staging (either CT of the chest-abdomen-pelvis or 18F-fluorodeoxyglucose positron emitting tomography (FDG-PET/CT)). CT is known to have relatively low sensitivity for detecting low volume metastatic disease, an important goal when considering surgical interventions entailing significant potential morbidity. FDG is also limited, being predominantly renally excreted and, therefore, producing intense non-specific activity in the urinary tract, which limits its utility to detect bladder and upper tract lesions, or nodal metastases in close proximity to the urinary tract. Read More

View Article and Full-Text PDF

Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria.

Eur Urol 2022 Apr 5. Epub 2022 Apr 5.

Academic Urology Unit, University of Aberdeen, Aberdeen, UK.

Context: The current impact of haematuria investigations on health care organisations is significant. There is currently no consensus on how to investigate patients with haematuria.

Objective: To evaluate the incidence of bladder cancer, upper tract urothelial carcinoma (UTUC), and renal cell carcinoma (RCC) among patients undergoing investigation for haematuria and identify any risk factors for bladder cancer, UTUC, and RCC (BUR). Read More

View Article and Full-Text PDF

Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers.

Exp Mol Pathol 2022 Jun 4;126:104762. Epub 2022 Apr 4.

Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Institute of Pathology, Clinical Center Osnabrueck, Osnabrueck, Germany.

Combined analysis of cytokeratin 7 (CK7) and cytokeratin 20 (CK20) is often used for assessing the origin of metastatic cancer. To evaluate the diagnostic utility of CK7 and CK20, tissue microarrays containing 15,424 samples from 120 different tumor types and subtypes and 608 samples of 76 different normal tissue types were analyzed by immunohistochemistry. CK7 positivity was seen in 52% (8. Read More

View Article and Full-Text PDF

Genitourinary Cancers Following Kidney Transplant: Our 20 Years of Experience With Mechanistic Target of Rapamycin Inhibitors.

Exp Clin Transplant 2022 03;20(Suppl 1):145-148

From the Department of General Surgery and Transplantation, University of Health Sciences, Izmir Faculty of Medicine, Bozyaka Education and Research Hospital, Izmir, Turkey.

Objectives: We investigated patients with genitourinary cancer after kidney transplant and the effects of immunosuppression reduction and switching to mechanistic target of rapamycin inhibitors.

Materials And Methods: We retrospectively evaluated kidney transplant recipients seen at our center between January 2000 and January 2020. Patients with <1 year of follow-up were excluded. Read More

View Article and Full-Text PDF

Incidental encounter of intraperitoneal tuberculosis during renal surgeries: A surgeon's dilemma.

Indian J Tuberc 2022 Apr 11;69(2):246-249. Epub 2021 Mar 11.

Department of Urology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, 249203 India.

Tuberculosis is a major healthcare burden in India, which accounts for the maximum number of cases worldwide. Due to its non-specific features, peritoneal tuberculosis has been dubbed as the great mimicker of various other abdominal pathologies. This case series highlights the importance of incidental intra operative detection of peritoneal tuberculosis in cases being operated for renal pathologies. Read More

View Article and Full-Text PDF

Urinary L-type fatty acid-binding protein is a predictor of cisplatin-induced acute kidney injury.

BMC Nephrol 2022 03 31;23(1):125. Epub 2022 Mar 31.

Department of Urology and Andrology, Graduate School of Medicine, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka, 573-1010, Japan.

Background: Although cisplatin-based chemotherapy is a standard treatment for urothelial carcinoma, it often causes acute kidney injury (AKI). AKI and dysfunction are observed in 25-35% of cisplatin-based chemotherapy patients, who may require treatment down-titration or withdrawal. In this study, we evaluated whether urinary L-FABP is a marker for early diagnosis of cisplatin-caused AKI. Read More

View Article and Full-Text PDF

Comparing costs of renal preservation versus radical nephroureterectomy management among patients with non-metastatic upper tract urothelial carcinoma.

Urol Oncol 2022 07 26;40(7):345.e1-345.e7. Epub 2022 Mar 26.

Department of Urology, University of California Los Angeles, Los Angeles, CA.

Background: To describe overall and categorical cost components in the management of patients with non-metastatic upper tract urothelial carcinoma (UTUC) according to treatment.

Methods: We identified 4,114 patients diagnosed with non-metastatic UTUC from 2004 to 2013 in the Survival Epidemiology and End Results-Medicare linked database. Patients were stratified into renal preservation (RP) vs. Read More

View Article and Full-Text PDF

The Prognostic Value and Immunological Role of STEAP1 in Pan-Cancer: A Result of Data-Based Analysis.

Oxid Med Cell Longev 2022 11;2022:8297011. Epub 2022 Mar 11.

Department of Oncology, Renmin Hospital of Wuhan University, Wuhan 430060, China.

Purpose: This study is aimed at systematically analyzing the expression, function, and prognostic value of six transmembrane epithelial antigen of the prostate 1 (STEAP1) in various cancers.

Methods: The expressions of STEAP1 between normal and tumor tissues were analyzed using TCGA and GTEx. Clinicopathologic data was collected from GEPIA and TCGA. Read More

View Article and Full-Text PDF

Reclassifying pT3 renal pelvic urothelial carcinoma with renal parenchyma invasion to pT2 improves correlation with overall survival.

Hum Pathol 2022 Jul 17;125:79-86. Epub 2022 Mar 17.

Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio 43201, USA. Electronic address:

The American Joint Cancer Committee pT categorization in renal pelvic carcinoma defines pT3 as invasion of renal parenchyma, invasion of peripelvic fat, or both. However, survival heterogeneity within the pT3 category has been demonstrated. This investigation sought to compare survival between pT categories of renal pelvic urothelial carcinoma and identify modifications to improve correlation with survival. Read More

View Article and Full-Text PDF

Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder.

Urol Oncol 2022 06 17;40(6):274.e15-274.e23. Epub 2022 Mar 17.

Division of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA. Electronic address:

Background: The role of adjuvant chemotherapy (AC) in patients with locally advanced bladder cancer following radical cystectomy (RC) remains uncertain, with contemporary clinical trials underpowered and closed early due to low accrual.

Objective: To conduct observational analyses designed to emulate a completed randomized trial of AC in patients with locally advanced bladder cancer.

Design, Settings, And Participants: Based on EORTC 30994 eligibility criteria, we identified adult patients aged 35 to 75 with pT3/pT4 Nany M0 or Tany pN1-3 M0, R0 urothelial carcinoma of the bladder treated with RC and lymphadenectomy from 2006 to 2015 in the National Cancer Database. Read More

View Article and Full-Text PDF

MicroRNA Signatures in the Upper Urinary Tract Urothelial Carcinoma Scenario: Ready for the Game Changer?

Int J Mol Sci 2022 Feb 26;23(5). Epub 2022 Feb 26.

Biorek S.r.l., San Raffaele Scientific Institute, 20132 Milan, Italy.

Upper urinary tract urothelial carcinoma (UTUC) represents a minor subgroup of malignancies arising in the urothelium of the renal pelvis or ureter. The estimated annual incidence is around 2 cases per 100,000 people, with a mean age at diagnosis of 73 years. UTUC is more frequently diagnosed in an invasive or metastatic stage. Read More

View Article and Full-Text PDF
February 2022

Optimal management of recurrent and metastatic upper tract urothelial carcinoma: Implications of intensity modulated radiation therapy.

Radiat Oncol 2022 Mar 9;17(1):51. Epub 2022 Mar 9.

Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemoon-gu, 03722, Seoul, Republic of Korea.

Background: Upper tract urothelial carcinoma (UTUC) is rare and the treatment for recurrent or metastatic UTUC is unclear. We evaluated the outcomes of salvage and palliative radiotherapy (RT) and prognostic factors in UTUC patients and find implications for salvage and palliative RT.

Methods: Between August 2006 and February 2021, 174 patients (median age, 68 years; range, 37-90) underwent salvage and palliative RT. Read More

View Article and Full-Text PDF

The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study.

ESMO Open 2022 04 2;7(2):100415. Epub 2022 Mar 2.

Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan. Electronic address:

Background: The comprehensive measurement of autoimmune disease-related antibodies (Abs) before immune checkpoint inhibitor (ICI) treatment may be useful for predicting the development of immune-related adverse events (irAEs); however, the clinical utility is not well known.

Materials And Methods: We retrospectively analyzed patients with advanced solid tumors treated with ICI monotherapy or doublet combination therapy between July 2014 and December 2020 at single institute. Anti-nuclear antibody (ANA), anti-thyroglobulin (Tg) Ab, anti-thyroid peroxidase (TPO) Ab, anti-glutamic acid decarboxylase (GAD) Ab, anti-acetylcholine esterase receptor (AchR) Ab, and platelet-associated immunoglobulin G (PA-IgG) Ab were comprehensively measured for the screening before ICI therapy. Read More

View Article and Full-Text PDF

Metastatic urothelial carcinoma of the urinary bladder in a Sumatran tiger (Panthera tigris sondaica).

Vet Med Sci 2022 05 3;8(3):1288-1293. Epub 2022 Mar 3.

Finn Pathologists, Histopathology Department, Diss, Norfolk, UK.

A 15-year-old spayed female Sumatran tiger (Panthera tigris sondaica) was presented with a short history of haematuria and dysuria, non-responsive to antibiotics, and a gradual decline to inappetence over a period of 2-3 months. Ultrasound examination showed a thickened urinary bladder wall and the renal pelvis of right kidney was dilated and cystic. A presumptive diagnosis of renal failure was made, and the tigress was euthanised due to deteriorating quality of life and pronounced weight loss. Read More

View Article and Full-Text PDF

Renal pelvis urothelial carinoma with trophoblastic cell differentiation: A case report.

Asian J Surg 2022 04 17;45(4):1059-1060. Epub 2022 Feb 17.

Department of Pathology, Gansu Provincial Hospital, Lanzhou, Gansu, 73000, China. Electronic address:

View Article and Full-Text PDF

Acute renal failure and bladder tumors, about 106 cases.

Nephrol Ther 2022 Jun 16;18(3):202-206. Epub 2022 Feb 16.

Department of Urology, Ibn-Rochd University Hospital, Casablanca, Morocco.

Objectives: The overall objective of the study was to determine the prevalence of acute renal failure due to bladder tumors by describing the clinical, paraclinical, therapeutic, histological and clinical evolution parameters.

Materials And Methods: Retrospective study over a period of 2 years dating from the first of September 2017 to the 31 of October 2019 on a number of patients with acute renal failure due to bladder tumors treated at the department of urology in the Ibn Roch teaching Hospital in Casablanca.

Results: In a series of 597 cases of bladder tumors, the prevalence of acute renal failure was 17. Read More

View Article and Full-Text PDF

Identification of Recurrent Insertions and Deletions in Exon 18 and 19 of Human Epidermal Growth Factor Receptor 2 as Potential Drivers in Non-Small-Cell Lung Cancer and Other Cancer Types.

JCO Precis Oncol 2022 02;6:e2100325

Department of Respiratory and Critical Medicine, Tianjin Chest Hospital, Tianjin, China.

Purpose: Human epidermal growth factor receptor 2 (HER2) belongs to the same family as epidermal growth factor receptor (EGFR) and is known as an important cancer driver gene. Insertions and deletions (indels) are frequent driver mutations in both EGFR and HER2. The most common HER2 indels are the exon 20 insertions within the kinase domain, while others are rarely reported. Read More

View Article and Full-Text PDF
February 2022

Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma.

CPT Pharmacometrics Syst Pharmacol 2022 04 27;11(4):458-468. Epub 2022 Feb 27.

Pfizer, San Diego, California, USA.

Avelumab is an anti-PD-L1 monoclonal antibody approved as monotherapy for Merkel cell carcinoma (MCC) and urothelial carcinoma (UC), and in combination with axitinib for advanced renal cell carcinoma (aRCC). Although initially approved with weight-based dosing (10 mg/kg intravenously [IV] every 2 weeks [Q2W]), avelumab was subsequently approved for flat dosing (800 mg IV Q2W) based on population pharmacokinetic (PopPK), exposure-efficacy, and exposure-safety modeling in MCC and UC. Here, through modeling and simulation, we provide justification for a flat-dose regimen of avelumab plus axitinib in aRCC. Read More

View Article and Full-Text PDF